Brief: Prelude Therapeutics Reports Full-Year 2022 Financial Results
15/03/2023 12:45
March 15 (Reuters) - Prelude Therapeutics Inc PRLD.O :
* PRELUDE THERAPEUTICS REPORTS FULL YEAR 2022 FINANCIAL
RESULTS
AND PROVIDES CORPORATE UPDATE
* PRELUDE THERAPEUTICS INC - CASH BALANCE OF $201.7 MILLION
AS OF
DECEMBER 31, 2022; RUNWAY REMAINS UNCHANGED THROUGH Q4 2024
Source text for Eikon: ID:nGNX3V5lxd
Further company coverage: PRLD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prelude Therapeutics Incorporated
See all newsBrief: Prelude Announces Clinical Trial Collaboration And Supply Agreement With Lilly To Evaluate KAT6A Selective Degrader PRT13722 In Combination With Verzenio® And Inluriyo® In Patients With HR+/HER2- Breast Cancer
U.S. RESEARCH ROUNDUP-Celcuity, Fluence Energy, Salesforce
Prelude Therapeutics Incorporated reports results for the quarter ended June 30 - Earnings Summary
Prelude Therapeutics Q2 revenue beats analyst expectations, net loss narrows
Prelude Therapeutics Incorporated expected to post a loss of 20 cents a share - Earnings Preview